This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| gigantism | |
|---|---|
| Name | Gigantism |
| Specialty | Endocrinology |
| Symptoms | Excessive linear growth, enlarged hands and feet, facial coarse features |
| Complications | Cardiomyopathy, diabetes mellitus, joint disease |
| Onset | Childhood or adolescence |
| Causes | Growth hormone excess due to pituitary adenoma |
| Diagnosis | Elevated insulin-like growth factor 1, oral glucose suppression test, pituitary MRI |
| Treatment | Transsphenoidal surgery, somatostatin analogues, radiotherapy |
gigantism
Gigantism is a rare pediatric endocrine disorder characterized by excessive linear growth and tissue overgrowth due to chronic hypersecretion of growth hormone during childhood and adolescence. It typically manifests with accelerated height velocity, acral enlargement, and systemic consequences affecting the cardiovascular, metabolic, and musculoskeletal systems. Clinical care often involves coordinated management by pediatric endocrinologists, neurosurgeons, radiotherapists, and geneticists.
Patients present with rapid increase in height, disproportionately large hands and feet, prognathism, and soft tissue swelling. Physical findings often include macroglossia, frontal bossing, and widened interdental spaces that prompt referral to pediatric endocrinology, orthopedics, and dentistry. Systemic manifestations commonly seen are cardiomegaly with heart failure risk, insulin resistance progressing to type 2 diabetes, and obstructive sleep apnea requiring evaluation by cardiology, pulmonology, and sleep medicine. Growth disturbance may be accompanied by headaches and visual field defects from mass effect, leading to consultations with neurosurgery, neuro-ophthalmology, and radiology.
The predominant cause is a somatotroph adenoma of the anterior pituitary producing excessive growth hormone, often associated with increased circulating insulin-like growth factor 1 from the liver; genetic contributors include germline variants in AIP, MEN1, McCune–Albright syndrome-related GNAS mutations, and other tumor predisposition genes requiring input from medical genetics and molecular pathology. Pathophysiology involves sustained growth hormone signaling through the JAK–STAT and MAPK pathways altering chondrocyte proliferation at epiphyseal growth plates and promoting soft tissue hypertrophy, with downstream metabolic effects mediated by insulin resistance. Large pituitary masses may invade the cavernous sinus, compress optic chiasm, and disrupt hypothalamic regulation, implicating neurosurgical and neuroendocrine expertise.
Diagnosis begins with measurement of serum insulin-like growth factor 1 relative to pediatric reference ranges and assessment of growth velocity by pediatric endocrinology teams; failure of growth hormone suppression during a standard oral glucose tolerance test confirms hypersecretion. Neuroimaging with pituitary magnetic resonance imaging is indicated to localize adenomas and assess extension into the cavernous sinus or sphenoid sinus, guiding neurosurgical planning. Additional evaluations include formal visual field testing by ophthalmology, echocardiography by cardiology, metabolic panels for glycemic status by endocrinology and clinical chemistry, and genetic testing coordinated with medical genetics when familial syndromes such as multiple endocrine neoplasia type 1 are suspected.
First-line therapy for most somatotroph adenomas is transsphenoidal adenomectomy performed by pituitary neurosurgeons to achieve biochemical remission and decompress the optic apparatus. Medical therapies include long-acting somatostatin analogues (octreotide, lanreotide) and the growth hormone receptor antagonist pegvisomant managed by endocrinology, with dopamine agonists like cabergoline considered in selected cases. Radiotherapy, including stereotactic radiosurgery administered by radiation oncology, is reserved for residual or recurrent disease or when surgery and medical therapy fail; lifelong endocrine surveillance is required for pituitary hormone deficiencies managed by multidisciplinary endocrine teams. Supportive care addresses cardiometabolic risk with cardiology and diabetes specialists, orthopedic interventions for joint disease, dental and maxillofacial surgery for craniofacial changes, and psychosocial support through pediatric psychiatry and social work.
Gigantism is rare, with incidence estimates derived from pituitary tumor registries and tertiary referral centers indicating far fewer cases than adult-onset growth hormone excess (acromegaly); prevalence varies geographically and among referral populations tracked by endocrinology and neurosurgery databases. Age of onset is typically pre-epiphyseal closure in childhood or adolescence, and sex distribution reflects slight male predominance reported in some cohorts collected by pediatric endocrine networks. Epidemiologic characterization often requires collaboration among international consortia, rare disease registries, and public health surveillance programs to capture familial syndromes and sporadic tumors.
Untreated disease leads to progressive cardiomyopathy, arrhythmia, uncontrolled diabetes mellitus, and increased morbidity from osteoarthritis and sleep-disordered breathing, necessitating coordinated care by cardiology, endocrinology, and pulmonology. Visual impairment may be permanent if optic chiasm compression persists prior to decompression by neurosurgery. Prognosis improves with early tumor resection, effective biochemical control with medical therapy, and longitudinal management of comorbidities by multidisciplinary teams such as pediatric endocrine clinics and pituitary centers of excellence.
Historical descriptions of extreme stature appear in medical literature, royal archives, and 19th-century case reports evaluated by medical historians and museum curators. Notable modern cases evaluated at academic centers and featured in biographies and institutional archives include patients studied by pioneers in endocrinology and neurosurgery at institutions such as the Mayo Clinic, Johns Hopkins Hospital, and University College London, with several familial cases linked to MEN1 centers and genetic research groups. Contemporary awareness has been advanced through case series published in journals of endocrinology and pituitary societies, and through multidisciplinary pituitary tumor boards at tertiary referral centers.